Previous 10 | Next 10 |
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term Loan Through January 2025 Maturity Date ENGLE...
2023-06-09 10:06:38 ET Aytu BioPharma ( NASDAQ: AYTU ) announced on Friday the pricing of its equity offering of 1.7M shares of its common stock and accompanying Tranche A and Tranche B warrants to purchase 4.3M shares of its common stock priced at-the-market. Offering co...
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term Loan Through January 2025 Maturity Date ENGL...
2023-05-11 21:57:01 ET Aytu BioPharma, Inc. (AYTU) Q3 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Partici...
2023-05-11 16:11:48 ET Aytu BioScience press release ( NASDAQ: AYTU ): Q3 GAAP EPS of -$1.93 misses by $1.30 . Revenue of $22.7M (-6.2% Y/Y) misses by $5.3M . For further details see: Aytu BioScience GAAP EPS of -$1.93 misses by $1.30, revenue of $22.7M m...
Total prescriptions increased 32% compared to Q3 2022 to highest level in Company history Company to host conference call today at 4:30pm ET ENGLEWOOD, CO / ACCESSWIRE / May 11, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and con...
2023-05-10 17:35:56 ET Aytu BioScience ( NASDAQ: AYTU ) is scheduled to announce FQ3 earnings results on Thursday, May 11th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue Estimate is $28M. For further details see: Aytu BioScie...
ENGLEWOOD, CO / ACCESSWIRE / May 4, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its ...
2023-05-02 10:02:29 ET Gainers: TScan Therapeutics ( TCRX ) +17% . Vivani Medical ( VANI ) +15% . SI-BONE ( SIBN ) +13% . Kiniksa Pharmaceuticals ( KNSA ) +12% . Harmony Biosciences ( HRMY ) +8% . Losers: Community Health ...
2023-05-02 08:27:58 ET GD Culture Group Limited ( GDC ) -48% . Chegg ( CHGG ) -47% after Q1 earning release . UTime Limited ( UTME ) -34% . Aytu BioPharma ( AYTU ) -29% . Tantech Holdings ( TANH ) -26% announces full year 2022 ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...